Evidence-First Compound Reviews
Built purely on published clinical studies and publicly available research data. We read the papers so you do not have to. Every study named, every limitation stated, every verdict graded.
Published Reviews
Reviewed by the Peptide Science Thailand Editorial Team.
Last reviewed: March 1, 2026
How We Score Peptide Evidence
Every peptide research review published on this site follows a structured editorial process designed to separate what the science actually shows from what the internet claims. The goal is not to promote or discourage any compound. It is to give readers an honest, study-level picture of the evidence so they can make informed decisions with their healthcare providers.
The 5-Point Evidence-Strength Scale
Each compound is rated across multiple therapeutic domains on a scale from 0 to 5. The score reflects the strength and quality of published clinical evidence, not biological plausibility alone and not popularity. Here is what each level means:
No published human data, or evidence directly contradicts the claim. Regulatory bodies may have flagged safety concerns.
Animal or in-vitro studies show biological activity. Human evidence, if any, is limited to small uncontrolled pilots. Clinical proof is absent.
Published RCTs or substantial controlled human trials exist. Higher scores require independent replication and regulatory recognition.
Editorial Process
Each review begins with a systematic literature search across PubMed, clinical trial registries such as ClinicalTrials.gov, and regulatory databases from the FDA, WADA, and other relevant bodies. We identify every available human study, catalog key animal studies for mechanistic context, and document regulatory positions.
Studies are graded individually. We distinguish sharply between randomised controlled trials, uncontrolled pilots, retrospective chart reviews, case reports, and preclinical animal work. The limitations of each study are stated explicitly: sample size, lack of blinding, absence of control groups, and conflicts of interest are all documented.
The editorial verdict synthesises the evidence into an honest assessment. We compare what social media and marketing commonly claim against what the published literature actually supports, and we identify the gaps. Every reference is cited with its PubMed ID or official URL so readers can verify the analysis independently.
Data Sources
Reviews reference peer-reviewed journals indexed in PubMed and PubMed Central, registered clinical trials from ClinicalTrials.gov, official regulatory statements from the U.S. FDA and international bodies, and anti-doping guidance from WADA and USADA. We do not rely on manufacturer claims, influencer testimonials, or unverified anecdotal reports.
Frequently Asked Questions
Each compound is rated on a 5-point evidence-strength scale across multiple therapeutic domains. We evaluate the quality, size, and design of available studies, distinguishing between animal models, uncontrolled human pilots, and randomised controlled trials. The final score reflects the weight of published clinical evidence, not popularity or anecdotal reports.
A score of 2.5 out of 5 indicates that preclinical (animal) evidence is promising but human clinical proof remains limited or absent. Studies may exist but tend to be small, uncontrolled, or lack independent replication. It signals biological plausibility without clinical validation.
Reviews are written by the Peptide Science Thailand editorial team. The process involves systematic literature searches across PubMed, clinical trial registries, and regulatory databases. Every claim is anchored to a named study, and every limitation is stated. We do not accept compensation from peptide manufacturers or vendors.
Reviews are updated when material new evidence is published, such as new clinical trial results, regulatory actions, or significant safety signals. Each review displays a "Last reviewed" date so readers can verify currency. We monitor PubMed alerts and trial registry updates for all covered compounds.
Most peptides in the consumer space lack large, well-designed human clinical trials. While animal research may be extensive and promising, the scoring system weights human evidence heavily. A compound with dozens of positive rodent studies but no published RCTs in humans will score below 3 because preclinical promise does not equal clinical proof.
We draw from peer-reviewed journals indexed in PubMed, clinical trial registries (ClinicalTrials.gov), and regulatory statements from bodies including the U.S. FDA, WADA, and USADA. Every reference is cited with its PubMed ID or official URL so readers can verify claims independently.